Caris Life Sciences, an Irving-Texas based company developing personalized cancer diagnostics and treatments, recently announced that 34 new clinical studies to be presented at the 50th Annual Meeting of American Society of Clinical Oncology (ASCO) utilized the company’s proprietary Caris Molecular Intelligence™ tumor profiling service. The ASCO event will be held from May 30th to June 3rd in Chicago.
At last year’s meeting, Caris presented three groups of results. This year, based on the 34 abstracts accepted by the Society, the company will be able to present further developments on their ongoing research and development.
In addition to the abstracts, ASCO also invited Caris to give two oral presentations — one of which will be given as a Clinical Science Symposium — and 20 poster presentations, seven of which will be poster highlight sessions.
A portion of the presented data is the result of research partnerships with academic and clinical institutions, namely Memorial Sloan-Kettering Cancer Center, the Mayo Clinic, Washington University, Ohio State University, and the Penn State Hershey Cancer Institute.
Caris’ goal is to work closely with the medical community to fulfill their commitment to provide cancer patients, particularly those with a rare or difficult-to-treat disease type, with the most targeted, effective treatment possible. To achieve this goal, the company developed Caris Molecular Intelligence, a tumor profiling system that analyzes each tumor and correlates its molecular data with drug associations from clinical cancer literature. This analysis of the patient’s disease information and previous research studies allows the system to determine which is the most efficient treatment for a particular type of cancer and cancer patient.
The new studies being presented at ASCO highlight Caris’ research and development results in advancing Caris Molecular Intelligence technology, which has led to an improvement of the system in determining more successful treatments for cancer patients.
The acceptance of these studies marks the first data presentation from the Caris Registry, an observational center that collects data from patients tested using its Molecular Intelligence platform and suffering from different types of tumors, including sarcoma, gastrointestinal cancers, and gynecologic malignities.
The schedule of Caris presentations at ASCO are:
- Saturday, May 31
General poster session: “The impact of tumor molecular profile-directed treatment on survival in recurrent ovarian cancer”
- Saturday, May 31
General poster session: “Molecular profiling of 6,892 colorectal cancer patients to identify potential targeted treatment options”
- Monday, June 2
Clinical Science Symposium: “Predictive biomarker profiling of >1900 sarcomas: Identification of potential novel treatment modalities”
- Monday, June 2
Poster highlight session: “Genomic and protein alterations in 126 triple negative (TN) metaplastic breast cancers”
- Tuesday, June 3
- Oral abstract session: “Expression of novel immunotherapeutic targets in triple negative breast cancer.”
Caris Life Science’s technology highlights distinct characteristics in a wide range of cancer types and improves, according to its CEO, David D. Halbert “each patient’s opportunity to defeat this dreaded disease.” Sandeep K. Reddy, senior medical director at Caris, added that the “emphasis on clinical utility is especially crucial for patients with rare, aggressive, or refractory cancers, who typically have significant therapeutic ambiguity.”